Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Observational Model: Cohort, Time Perspective: Prospective
frequency of "actionable" oncogenic mutations
"Actionable" mutations will be defined as either 1) a mutation shown to predict for sensitivity or resistance to a drug FDA approved for use in another cancer indication or 2) a mutation which predicts for sensitivity or resistance in preclinical models to an investigational class of drugs.
David Hyman, MD
Memorial Sloan-Kettering Cancer Center
United States: Institutional Review Board
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|